KR102598180B1 - 항-트랜스타이레틴 항체 - Google Patents

항-트랜스타이레틴 항체 Download PDF

Info

Publication number
KR102598180B1
KR102598180B1 KR1020177023749A KR20177023749A KR102598180B1 KR 102598180 B1 KR102598180 B1 KR 102598180B1 KR 1020177023749 A KR1020177023749 A KR 1020177023749A KR 20177023749 A KR20177023749 A KR 20177023749A KR 102598180 B1 KR102598180 B1 KR 102598180B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
ttr
delete delete
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177023749A
Other languages
English (en)
Korean (ko)
Other versions
KR20170106469A (ko
Inventor
유에 리우
타를로칸 에스. 니자
아비짓 채크라바티
제프리 엔. 히가키
Original Assignee
프로테나 바이오사이언시즈 리미티드
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테나 바이오사이언시즈 리미티드, 유니버시티 헬스 네트워크 filed Critical 프로테나 바이오사이언시즈 리미티드
Priority to KR1020237037602A priority Critical patent/KR102677203B1/ko
Publication of KR20170106469A publication Critical patent/KR20170106469A/ko
Application granted granted Critical
Publication of KR102598180B1 publication Critical patent/KR102598180B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177023749A 2015-01-28 2016-01-28 항-트랜스타이레틴 항체 Active KR102598180B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237037602A KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109002P 2015-01-28 2015-01-28
US62/109,002 2015-01-28
US201562266556P 2015-12-11 2015-12-11
US62/266,556 2015-12-11
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037602A Division KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Publications (2)

Publication Number Publication Date
KR20170106469A KR20170106469A (ko) 2017-09-20
KR102598180B1 true KR102598180B1 (ko) 2023-11-03

Family

ID=55299694

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177023749A Active KR102598180B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체
KR1020237037602A Active KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237037602A Active KR102677203B1 (ko) 2015-01-28 2016-01-28 항-트랜스타이레틴 항체

Country Status (31)

Country Link
US (1) US20160251418A1 (enExample)
EP (2) EP3250592B1 (enExample)
JP (2) JP6748086B2 (enExample)
KR (2) KR102598180B1 (enExample)
CN (1) CN107406499B (enExample)
AU (1) AU2016210888C1 (enExample)
CA (1) CA2974912A1 (enExample)
CL (2) CL2017001924A1 (enExample)
CO (1) CO2017008476A2 (enExample)
CU (1) CU24480B1 (enExample)
DK (1) DK3250592T3 (enExample)
EA (1) EA036080B1 (enExample)
ES (1) ES2934656T3 (enExample)
FI (1) FI3250592T3 (enExample)
HR (1) HRP20221538T1 (enExample)
HU (1) HUE060878T2 (enExample)
IL (1) IL253633B (enExample)
LT (1) LT3250592T (enExample)
MX (1) MX394170B (enExample)
PE (1) PE20180217A1 (enExample)
PH (1) PH12017501318B1 (enExample)
PL (1) PL3250592T3 (enExample)
PT (1) PT3250592T (enExample)
RS (1) RS63906B1 (enExample)
SA (1) SA517382002B1 (enExample)
SG (2) SG11201706124VA (enExample)
SI (1) SI3250592T1 (enExample)
TW (2) TWI786505B (enExample)
UA (1) UA122142C2 (enExample)
WO (1) WO2016120810A1 (enExample)
ZA (1) ZA201705663B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7076711B2 (ja) * 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2019071206A1 (en) * 2017-10-06 2019-04-11 Prothena Biosciences Limited METHODS OF DETECTING TRANSTHYRETIN
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
MX2020005433A (es) * 2017-11-29 2020-08-27 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
US20210400932A1 (en) 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
EP4121766A1 (en) 2020-03-18 2023-01-25 AL-S Pharma AG Misfolded sod1 assay
MX2022014223A (es) 2020-05-12 2023-04-14 Neurimmune Ag Terapia de combinacion para amiloidosis de la ttr.
US20230340089A1 (en) * 2020-05-14 2023-10-26 City Of Hope Smc1a antibodies and uses thereof
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
JP2024544924A (ja) * 2021-11-12 2024-12-05 エーディーアールエックス， インコーポレイテッド トランスサイレチン（ｔｔｒ）単量体結合抗体
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
JP2026505138A (ja) * 2022-10-19 2026-02-12 アイバイオ， インク． ケモカイン受容体８（ｃｃｒ８）抗体
EP4619431A1 (en) 2022-11-15 2025-09-24 Neurimmune AG Methods for treating or preventing transthyretin-mediated amyloidosis
TW202440636A (zh) * 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
EP4713354A1 (en) 2023-05-19 2026-03-25 Neurimmune AG Novel immunotherapy for musculoskeletal disorders and conditions
WO2025104243A1 (en) 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis
WO2025125544A1 (en) 2023-12-15 2025-06-19 Novo Nordisk A/S Stable liquid formulations
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2015010118A2 (en) 2013-07-19 2015-01-22 The University Of Texas Transthyretin amyloid-selective and polyreactive catabodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MXPA01007845A (es) 1999-02-05 2004-06-22 Samsung Electronics Co Ltd Metodo para la recuperacion de la textura de imagenes y aparato para el mismo.
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
SI2126093T1 (sl) 2007-03-02 2013-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Izboljšanje priprave proteinov
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
WO2019071206A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited METHODS OF DETECTING TRANSTHYRETIN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056904A1 (en) 2012-08-24 2014-02-27 University Health Network Antibodies to TTR and Methods of Use
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2015010118A2 (en) 2013-07-19 2015-01-22 The University Of Texas Transthyretin amyloid-selective and polyreactive catabodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PNAS, 제96권, 제6호, 제3108-3113면 (1999. 3. 16.)
Rejuvenation Research, 제17권, 제2호, 제97-104면 (2014. 4.)

Also Published As

Publication number Publication date
CL2022003027A1 (es) 2023-06-09
EA201791712A1 (ru) 2017-12-29
JP7028923B2 (ja) 2022-03-02
CU24480B1 (es) 2020-03-04
PH12017501318A1 (en) 2018-02-05
AU2016210888A1 (en) 2017-08-10
SG10202101763VA (en) 2021-04-29
CO2017008476A2 (es) 2018-01-16
BR112017016330A2 (en) 2018-04-03
CN107406499A (zh) 2017-11-28
TWI718122B (zh) 2021-02-11
NZ733896A (en) 2024-11-29
CU20170097A7 (es) 2018-03-13
JP2018506277A (ja) 2018-03-08
KR20230156164A (ko) 2023-11-13
RS63906B1 (sr) 2023-02-28
PT3250592T (pt) 2022-12-28
TW202124436A (zh) 2021-07-01
IL253633B (en) 2021-06-30
US20160251418A1 (en) 2016-09-01
KR20170106469A (ko) 2017-09-20
AU2016210888B2 (en) 2021-11-04
UA122142C2 (uk) 2020-09-25
EP4134379A1 (en) 2023-02-15
ES2934656T3 (es) 2023-02-23
AU2016210888C1 (en) 2022-06-02
ZA201705663B (en) 2018-08-29
WO2016120810A1 (en) 2016-08-04
LT3250592T (lt) 2023-02-10
HUE060878T2 (hu) 2023-04-28
JP6748086B2 (ja) 2020-09-02
SA517382002B1 (ar) 2021-11-25
SG11201706124VA (en) 2017-08-30
TW201632554A (zh) 2016-09-16
PE20180217A1 (es) 2018-01-31
MX394170B (es) 2025-03-24
PH12017501318B1 (en) 2018-02-05
JP2020185009A (ja) 2020-11-19
CL2017001924A1 (es) 2018-04-27
MX2017009806A (es) 2018-08-15
EA036080B1 (ru) 2020-09-23
IL253633A0 (en) 2017-09-28
CA2974912A1 (en) 2016-08-04
KR102677203B1 (ko) 2024-06-20
EP3250592A1 (en) 2017-12-06
FI3250592T3 (fi) 2023-01-13
SI3250592T1 (sl) 2023-03-31
EP3250592B1 (en) 2022-10-05
DK3250592T3 (en) 2023-01-09
CN107406499B (zh) 2021-10-22
TWI786505B (zh) 2022-12-11
PL3250592T3 (pl) 2023-06-19
HRP20221538T1 (hr) 2023-03-03

Similar Documents

Publication Publication Date Title
KR102598180B1 (ko) 항-트랜스타이레틴 항체
KR102649788B1 (ko) 항-트랜스타이레틴 항체
KR102619359B1 (ko) 항-트랜스타이레틴 항체
US10669330B2 (en) Anti-transthyretin antibodies
US11629185B2 (en) Anti-transthyretin antibodies
KR20200074956A (ko) 항-트랜스타이레틴 항체
US11267878B2 (en) Anti-transthyretin antibodies
JP2019532617A (ja) 抗トランスサイレチン抗体
HK1240247A1 (en) Anti‐transthyretin antibodies
HK1240247B (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210127

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20221116

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230506

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230801

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231031

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231101

End annual number: 3

Start annual number: 1

PG1601 Publication of registration